Form D · Other Health Care

ZIMMER BIOMET HOLDINGS, INC.

Warsaw, IN · CIK 1136869

Offering snapshot reported Feb 15, 2023 · SEC filing

Reported sold: $216M
Investors reported: 157
Minimum accepted: $0
First sale: Feb 6, 2023

What changed?

Latest filing versus its linked predecessor, where available.

No comparable changes in the displayed metrics.

Filing history

Scroll to see all columns →

Filed	Filing type	Reported sold	Change vs linked filing	Investors	Source
Feb 15, 2023	Initial	$216,086,331	No comparison	157	SEC filing

Offering details

Securities: Equity
Exemptions: 06b
Duration over one year: No
Business combination: Yes

Sales commissions: $0
Finders' fees: $0
Form D file number: 021-473567

The securities have been or may be issued as partial consideration for Embody, Inc. merger. Value above is based on agreed value of shares under merger agreement terms, and includes maximum potential shares associated with future earn-out contingencies.

Source: Form D, filed Feb 15, 2023. Minimum accepted may differ from a standard advertised minimum.

Fund connections

No confirmed ADV fund connection is available for this issuer.

People & organizations

Current and past Form D appearances. These existing records do not establish a person's current role or uniquely identify them across issuers.

People and organizations reported in Form D filings
Name	Reported role
Christopher B. Begley	Director
Betsy J. Bernard	Director
Rachel Ellingson	Executive
Michael J. Farrell	Director
Robert A. Hagemann	Director
Bryan C. Hanson	Director, Executive
Arthur J. Higgins	Director
Maria Teresa Hilado	Director
Syed A. Jafry	Director
Sreelakshmi Kolli	Director
Michael W. Michelson	Director
Chad F. Phipps	Executive
Paul A. Stellato	Executive
Ivan Tornos	Executive
Suketu Upadhyay	Executive
Wilfred Van Zuilen	Executive
Lori Winkler	Executive
Sang Yi	Executive

Issuer details

Industry: Other Health Care (See others in industry)

Address:

345 East Main Street
Warsaw, IN, 46580